SPAIN – Bruker Corporation, a leader in the post-genomic era, has showcased its latest innovations at the ESCMID Global 2024 conference in a bid to revolutionize microbial identification, antimicrobial susceptibility testing, and infectious disease diagnostics. 

With a focus on streamlining clinical workflows and enhancing patient care, Bruker introduced novel diagnostic tools aimed at expediting treatment decisions and improving outcomes.

Automated sample preparation for microbial identification

Bruker introduced the MBT Pathfinder® IVD robot, designed to automate target preparation for the MALDI Biotyper® system. 

This advancement promises to eliminate time-consuming manual tasks, enhancing efficiency and accuracy in microbial identification. 

According to Dr. Wolfgang Pusch, President of the Bruker Microbiology & Infection Diagnostics division, this innovation marks a significant step towards simplifying microbiology workflows in clinical laboratories.

Rapid sepsis diagnosis

Time is of the essence in treating sepsis, and Bruker’s latest offerings aim to expedite pathogen identification. 

The IVD-CE MALDI Biotyper®, coupled with the MBT Sepsityper® IVD Kit, enables the identification of pathogens within 20 minutes from positive blood cultures. 

Additionally, Bruker provides clinical workflows for rapid antibiotic resistance testing, facilitating timely and targeted treatment strategies.

Accurate antimicrobial susceptibility testing

Antimicrobial susceptibility testing (AST) is crucial for guiding antibiotic therapy, and Bruker’s UMIC® tests deliver precise results for single antibiotics and combinations. 

The MICRONAUT range offers AST of multiple antibiotics in a single test, streamlining laboratory workflows while ensuring compliance with CLSI/EUCAST recommendations. 

These advancements empower healthcare professionals to make informed treatment decisions tailored to individual patient needs

Looking ahead, Bruker is focused on further enhancing microbial identification and AST capabilities. 

The development of the MBT-fAST assay aims to enable rapid AST of gram-negative bacteria directly from positive blood cultures, promising faster turnaround times and improved patient care. 

Moreover, ongoing efforts in lipid A-based colistin resistance detection underscore Bruker’s commitment to combating antimicrobial resistance.

In a strategic move to bolster its capabilities, Bruker Corporation’s pending acquisition of ELITechGroup has received all regulatory clearances. 

With the closing of the acquisition expected in the second quarter of 2024, Bruker is poised to expand its footprint in the clinical microbiology and molecular diagnostics arena.

By enabling scientists and engineers to make breakthrough discoveries and develop new applications, Bruker is advancing human health and quality of life across various domains, from molecular and cell biology research to clinical microbiology and molecular diagnostics.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook